Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 3-Hydroxybenzylhydrazine Dihydrochloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.53 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.53 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.44 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.44 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | PKM | P14618 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL31298984 | 1.00 | MAPT (1.00) | MAPTKDM4ELMNAKMT2ABLM | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL1309761 | 1.00 | MAPT (1.00) | MAPTKDM4ELMNAKMT2ABLM | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL31298981 | 1.00 | MAPT (1.00) | MAPTKDM4ELMNAKMT2ABLM | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL160617 | 0.98 | CYP3A4 (1.00) | MAPTKDM4ELMNAKMT2ABLM | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL29594115 | 0.98 | CYP3A4 (1.00) | MAPTKDM4ELMNAKMT2ABLM | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL23645200 | 0.89 | CYP3A4 (0.82) | MAPTKDM4ELMNAKMT2ABLM | |
| SCHEMBL28584924 | 0.82 | CYP3A4 (0.71) | MAPTKDM4ELMNAKMT2ABLM | |
| SCHEMBL14923237 | 0.82 | CYP3A4 (0.71) | MAPTKDM4ELMNAKMT2ABLM | |
| SCHEMBL9416529 | 0.80 | SLC2A4 (0.75) | MAPTKDM4ELMNAKMT2ABLM | |
| SCHEMBL6898308 | 0.78 | CYP3A4 (0.67) | MAPTKDM4ELMNAKMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3274004-B1 | CONTROLLED RELEASE MATRIX BARRIER STRUCTURE FOR SUBCUTANEOUS MEDICAL DEVICES | SURMODICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11052177-B2 | Antimicrobial polymer layers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-07-06 | — | — | US | disclosed |
| EP-2611868-B1 | BIODEGRADABLE TERPOLYMERS AND TERPOLYMER BLENDS AS PRESSURE-SENSITIVE ADHESIVES | SURMODICS PHARMACEUTICALS INC (US) | 2020-01-08 | — | — | EP | disclosed |
| US-10322209-B2 | Polyurethanes for osteoimplants | WARSAW ORTHOPEDIC, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10308943-B2 | Compositions with improved intravitreal half-life and uses thereof | VITRISA THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180340179-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | SILICON VALLEY BANK | 2018-11-29 | — | — | US | disclosed |
| US-10117974-B2 | Non-fouling, anti-microbial, anti-thrombogenic graft-from compositions | ARROW INTERNATIONAL, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180263919-A1 | THERAPEUTIC ELECTROSPUN FIBER COMPOSITIONS | UNIV JOHNS HOPKINS (US) | 2018-09-20 | — | — | US | disclosed |
| US-20180250442-A1 | POLYURETHANES FOR OSTEOIMPLANTS | WARSAW ORTHOPEDIC INC (US) | 2018-09-06 | — | — | US | disclosed |
| EP-1434608-B1 | IMPROVED BONE GRAFT | WARSAW ORTHOPEDIC INC (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-0064964-B1 | THERAPEUTICALLY USEFUL 1-ALKYL-2-AMINOTETRALIN DERIVATIVES | Astra Läkemedel Aktiebolag (SE) | 1984-08-08 | — | — | EP | disclosed |
| US-4426386-A | CNS DISORDERS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1984-01-17 | — | — | US | disclosed |
| EP-0097628-A2 | Piperidine derivatives, processes for their preparation and pharmaceutical preparation containing them | Carlsson, Per Arvid Emil (SE) | 1984-01-04 | — | — | EP | disclosed |
| EP-0091437-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES III, PROCESSES FOR PREPARATION AND PHARMACEUTICAL PREPARATIONS FOR SUCH COMPOUNDS | Arvidsson, Folke Lars-Erik (SE) | 1983-10-19 | — | — | EP | disclosed |
| EP-0084920-A2 | New compounds useful as intermediates or starting materials for preparation of therapeutically useful phenyl-azacycloalkanes | Carlsson, Per Arvid Emil (SE) | 1983-08-03 | — | — | EP | disclosed |
| WO-1982004042-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES III,PROCESSES FOR PREPARATION AND PHARMACEUTICAL PREPARATIONS FOR SUCH COMPOUNDS | ARVIDSSON FOLKE LARS ERIK | 1982-11-25 | — | — | WO | disclosed |
| EP-0064964-A1 | Therapeutically useful 1-alkyl-2-aminotetralin derivatives | Astra Läkemedel Aktiebolag (SE) | 1982-11-17 | — | — | EP | disclosed |
| WO-1981003491-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | ASTRA LAEKEMEDEL AB (SE) | 1981-12-10 | — | — | WO | disclosed |
| EP-0041488-A1 | Therapeutically useful tetralin derivatives | Arvidsson, Folke Lars-Erik (SE) | 1981-12-09 | — | — | EP | disclosed |
| EP-0030526-A1 | New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds | Astra Läkemedel Aktiebolag (SE) | 1981-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263919-A1 | THERAPEUTIC ELECTROSPUN FIBER COMPOSITIONS | NGF, BDNF, NTRK2 | DRD2 4751/4885DRD1 4830/4885CHRM2 4096/4885 |
| US-20180340179-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | UACA, CRYAA, CRYAB | DRD2 3814/4885DRD1 3637/4885CHRM2 3642/4885 |
| US-10308943-B2 | Compositions with improved intravitreal half-life and uses thereof | UACA, CRYAA, CRYAB | DRD2 3814/4885DRD1 3637/4885CHRM2 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.